PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery
Status:
Recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an
open- label,single center,non-randomized ,single arm exploratory study . This clinical study
is an investigator-initiated clinical trial(IIT) .The objective of this study is to evaluate
the efficacy and safety of therapy with anti-PD-1 antibody SHR-1210 plus Capecitabine in
patients with Intrahepatic Cholangiocarcinoma After Surgery.